• Kazia Therapeutics expanded its ongoing TNBC trial into HR+/HER2- advanced breast cancer to test paxalisib-based combinations.
• New preclinical results were presented now, showing the combinations were well tolerated and reduced tumor growth in HR+ models.
• Data also suggest paxalisib may restore sensitivity in tumors resistant to CDK4/6 inhibitors, supporting a potential differentiation versus rivals.
• First patient is expected before end-2026; full enrollment is targeted by end-2027; full study readout is slated for 2028.
• Additional comparative preclinical data are scheduled for later in 2026, with clinical updates expected through 2027.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Kazia Therapeutics Limited published the original content used to generate this news brief via PR Newswire (Ref. ID: 202609010715PR_NEWS_USPR_____NY37501) on September 01, 2026, and is solely responsible for the information contained therein.